In Taiwan, the clinical data submission guidelines for biologics require applicants to provide comprehensive clinical trial data proving safety, efficacy, and immunogenicity. Submissions must follow ICH standards and include pharmacokinetics and pharmacodynamics data. The TFDA may require bridging studies to confirm the relevance of foreign data for the local population.